Vir ex-officer sold $315K in stock on Sept. 9

Former officer Jason V. O'Byrne files a Rule 144 notice for planned Vir Biotechnology stock sales after recent multi-day selling activity.

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) has a notice from former officer Jason V. O'Byrne covering planned sales of common stock under Rule 144. The notice lists multiple tranches of common shares to be sold that were or will be acquired through restricted stock vesting on November 15, 2025, November 28, 2025, February 23, 2026, and February 24, 2026, and through an ESPP purchase on May 29, 2026. It also reports that O'Byrne has already sold several blocks of Vir common stock in recent months, including 25,000 shares for $245,297.50 on August 21, 2026, and additional sales on August 24, August 25, and September 9, 2026.

Key Figures

Sale on August 21, 2026: 25,000 shares; $245,297.50 gross proceeds Sale on August 24, 2026: 14,352 shares; $142,123.55 gross proceeds Sale on August 25, 2026: 23,148 shares; $242,591.04 gross proceeds +4 more

7 metrics

Sale on August 21, 2026 25,000 shares; $245,297.50 gross proceeds Common stock sold by Jason V. O'Byrne

Sale on August 24, 2026 14,352 shares; $142,123.55 gross proceeds Common stock sold by Jason V. O'Byrne

Sale on August 25, 2026 23,148 shares; $242,591.04 gross proceeds Common stock sold by Jason V. O'Byrne

Sale on September 9, 2026 28,333 shares; $315,241.46 gross proceeds Common stock sold by Jason V. O'Byrne

Restricted stock vesting 11/15/2025 11,951 shares Vir common stock listed as securities to be sold from compensation vesting

Restricted stock vesting 02/24/2026 3,366 shares Vir common stock listed as securities to be sold from compensation vesting

ESPP purchase 05/29/2026 492 shares Vir common stock acquired through ESPP purchase listed to be sold for cash

Key Terms

Rule 144, restricted stock vesting, ESPP Purchase, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Common | 11/15/2025 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

ESPP Purchase financial

"Common | 05/29/2026 | ESPP Purchase | Issuer"

attorney-in-fact regulatory

"as attorney-in-fact for Jason V. O'Byrne"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Vir Biotechnology (VIR) disclose about Jason V. O'Byrne's planned stock sales?

The notice shows that former officer Jason V. O'Byrne plans to sell Vir common stock acquired through restricted stock vesting on November 15, 2025, November 28, 2025, February 23, 2026, and February 24, 2026, and through an ESPP purchase on May 29, 2026.

How many Vir (VIR) shares from the November 15, 2025 vesting are covered in the Form 144?

The filing lists 11,951 shares of Vir common stock from restricted stock vesting dated November 15, 2025, as securities to be sold for compensation-related purposes.

What recent Vir (VIR) stock sales by Jason V. O'Byrne are reported?

The notice reports that Jason V. O'Byrne sold 25,000 shares of Vir common stock for $245,297.50 on August 21, 2026, with additional common stock sales on August 24, 2026, August 25, 2026, and September 9, 2026.

What Vir (VIR) sale occurred on August 24, 2026 for Jason V. O'Byrne?

On August 24, 2026, Jason V. O'Byrne sold 14,352 shares of Vir common stock for $142,123.55, as reported in the recent activity section of the notice.

What Vir (VIR) sale occurred on August 25, 2026 for Jason V. O'Byrne?

On August 25, 2026, Jason V. O'Byrne sold 23,148 shares of Vir common stock for $242,591.04, according to the transactions listed in the filing.

What Vir (VIR) sale occurred on September 9, 2026 for Jason V. O'Byrne?

On September 9, 2026, Jason V. O'Byrne sold 28,333 shares of Vir common stock for $315,241.46, as disclosed in the section detailing securities sold during the past three months.

Who signed the Vir (VIR) Form 144 related to Jason V. O'Byrne?

The notice is signed /s/ Wade Moss as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Jason V. O'Byrne, dated September 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 10:15 AM Accepted by SEC EDGAR 09/17/2026 - 10:15 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001871145
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	O'Byrne Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	19357	212927.00	169215958	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/15/2025	Restricted Stock Vesting	Issuer			11951	11/15/2025	Compensation
Common	11/28/2025	Restricted Stock Vesting	Issuer			637	11/28/2025	Compensation
Common	02/23/2026	Restricted Stock Vesting	Issuer			2911	02/23/2026	Compensation
Common	02/24/2026	Restricted Stock Vesting	Issuer			3366	02/24/2026	Compensation
Common	05/29/2026	ESPP Purchase	Issuer			492	05/29/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/21/2026	25000	245297.50
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/24/2026	14352	142123.55
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	08/25/2026	23148	242591.04
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	09/09/2026	28333	315241.46

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jason V. O'Byrne
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)